These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32452564)

  • 1. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
    Lee HA; Lee HW; Kim IH; Park SY; Sinn DH; Yu JH; Seo YS; Um SH; Lee JI; Lee KS; Lee CH; Tak WY; Kweon YO; Kang W; Paik YH; Lee JW; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU
    Aliment Pharmacol Ther; 2020 Jul; 52(1):196-204. PubMed ID: 32452564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Kim GA; Han S; Choi GH; Choi J; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
    Choi GH; Kim GA; Choi J; Han S; Lim YS
    Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase.
    Lee HW; Kim EH; Lee J; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00140. PubMed ID: 32352711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT.
    Duan M; Xiao H; Shi M; Xie Y; Zhao P; Li S; Chi X; Liu X; Zhuang H
    BMC Infect Dis; 2024 Jul; 24(1):723. PubMed ID: 39044129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune-tolerant phase of chronic hepatitis B virus infection: A systematic review and meta-analysis.
    Liu M; Zhao T; Zhang J; Bu B; Zhang R; Xia X; Geng J
    Rev Med Virol; 2024 Jul; 34(4):e2570. PubMed ID: 38964866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.
    Lee HW; Chon YE; Kim BK; Yip TC; Tse YK; Wong GL; Wong VW; Chan HL; Ahn SH
    Eur J Intern Med; 2021 Feb; 84():68-73. PubMed ID: 33288393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic Model.
    Kim GA; Lim YS; Han S; Choi GH; Choi WM; Choi J; Sinn DH; Paik YH; Lee JH; Lee YB; Cho JY; Heo NY; Yuen MF; Wong VW; Chan SL; Yang HI; Chen CJ
    Ann Intern Med; 2024 Oct; 177(10):1308-1318. PubMed ID: 39284185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
    Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
    Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
    J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
    Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
    Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.
    Chen CF; Lee WC; Yang HI; Chang HC; Jen CL; Iloeje UH; Su J; Hsiao CK; Wang LY; You SL; Lu SN; Chen CJ;
    Gastroenterology; 2011 Oct; 141(4):1240-8, 1248.e1-2. PubMed ID: 21703214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.